暂无分享,去创建一个
Jitendra Jonnagaddala | Hong Zhang | Xingyu Li | Shuhua Yang | Xu Steven Xu | J. Jonnagaddala | Hong Zhang | Xuesong Xu | Xingyu Li | Shuhua Yang
[1] F. D. De Braud,et al. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] D. Kerr,et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] F. Marincola,et al. Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] S. Shchegrova,et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer , 2019, JAMA oncology.
[5] Peter Regitnig,et al. Interpretable survival prediction for colorectal cancer using deep learning , 2021, npj Digital Medicine.
[6] A. Madabhushi,et al. Artificial intelligence in digital pathology — new tools for diagnosis and precision oncology , 2019, Nature Reviews Clinical Oncology.
[7] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[8] F. Marincola,et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.
[9] Steven J. M. Jones,et al. Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.
[10] J. Hecht,et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. , 2012, The Lancet. Oncology.
[11] R. Labianca,et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] Constantino Carlos Reyes-Aldasoro,et al. Predicting survival from colorectal cancer histology slides using deep learning: A retrospective multicenter study , 2019, PLoS medicine.
[13] Jitendra Jonnagaddala,et al. Whole slide images based cancer survival prediction using attention guided deep multiple instance learning networks , 2020, Medical Image Anal..
[14] I Tomlinson,et al. Prognostic markers for colorectal cancer: estimating ploidy and stroma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] J. Ptak,et al. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. , 2019, JAMA oncology.
[16] N. Petrelli,et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Lin Wang,et al. Prognostic value of nucleotyping, DNA ploidy and stroma in high-risk stage II colon cancer , 2020, British Journal of Cancer.
[18] S. Paik,et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] C. Compton,et al. The Staging of Colorectal Cancer: 2004 and Beyond , 2004, CA: a cancer journal for clinicians.
[20] C. Begg,et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Margarita Lopatin,et al. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Marco Novelli,et al. Deep learning for prediction of colorectal cancer outcome: a discovery and validation study , 2020, The Lancet.
[23] T. Hickish,et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Jeffrey S. Morris,et al. The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.
[25] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[26] Ahmed Kamel,et al. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.
[27] Robyn Ward,et al. Integration and Analysis of Heterogeneous Colorectal Cancer Data for Translational Research , 2016, Nursing Informatics.